Hirsutism, Hair Loss, and Hormonal Hair Disorders: Causes, Diagnosis, and Treatments

What Is Hirsutism and How Is It Diagnosed?

Hirsutism is the growth of coarse, pigmented, terminal hair on women in androgen-dependent body sites, specifically the face, chest, abdomen, back, and inner thighs. It is not the same as hypertrichosis, which is generalized excess hair growth independent of androgens. Diagnosis uses the modified Ferriman-Gallwey (mFG) scoring system, where clinicians rate nine body areas from 0 to 4; a total score of 8 or more confirms hirsutism in most populations, though some guidelines use a lower cutoff of 6 for East Asian women.

The Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend using the modified Ferriman-Gallwey score to quantify the degree of hirsutism and to monitor treatment response." [1] Laboratory workup typically begins with a total and free testosterone level. A total testosterone above 200 ng/dL raises suspicion for an androgen-secreting tumor and warrants imaging. A DHEA-S above 700 mcg/dL points toward an adrenal source. Free androgen index and sex hormone-binding globulin (SHBG) levels help clarify bioavailability.

PCOS is the underlying diagnosis in roughly 72-82% of hirsutism cases, as confirmed in a systematic review of 1,742 women published in the European Journal of Endocrinology [2]. Idiopathic hirsutism, defined as an mFG score of 8 or higher with normal androgen levels and regular cycles, accounts for most remaining cases. Congenital adrenal hyperplasia (non-classical form), thyroid dysfunction, and hyperprolactinemia round out the differential. Rarer causes, including Cushing syndrome and androgen-secreting tumors, require exclusion when onset is rapid or virilization is present.

How Androgens Drive Both Hirsutism and Pattern Hair Loss

The same hormonal axis that causes excess body hair in women also drives miniaturization of scalp follicles in both sexes. Dihydrotestosterone (DHT), produced from testosterone by the enzyme 5-alpha reductase type II, binds androgen receptors in hair follicles. In androgen-sensitive scalp follicles, DHT shortens the anagen (growth) phase and progressively miniaturizes the follicle over successive cycles. In facial and body follicles, DHT has the opposite effect, promoting terminal hair growth from vellus precursors.

Genetic variation in the androgen receptor gene (AR), located on the X chromosome, explains a significant portion of susceptibility to male pattern hair loss [3]. A genome-wide association study published in PLOS Genetics (N=52,506) identified 63 loci associated with male-pattern baldness, with AR-region variants carrying the largest effect sizes [3]. Women with PCOS exhibit higher free testosterone and DHT levels compared to age-matched controls, which is why a subset of PCOS patients present with both hirsutism and female pattern hair loss simultaneously.

The table below illustrates how the same androgen excess produces divergent outcomes at different follicle types, a framework the HealthRX clinical team uses to explain co-existing hirsutism and scalp hair thinning to patients:

| Follicle location | Response to high DHT | |---|---| | Scalp (genetically sensitive) | Miniaturization, shortened anagen, eventual loss | | Face/body (androgen-responsive) | Conversion from vellus to terminal hair | | Scalp (androgen-insensitive, e.g., occipital) | No significant change |

This divergence explains why a woman with PCOS can simultaneously present with chin hair and diffuse crown thinning, and why the treatment goal is to lower androgen activity systemically or block its receptor at the follicle.

Male Pattern Hair Loss: Causes and FDA-Approved Treatments

Male pattern hair loss (MPHL), also called androgenetic alopecia, follows the Hamilton-Norwood classification from Stage I (minimal recession) to Stage VII (complete crown and vertex loss with residual horseshoe band). Approximately 50% of men show some degree of MPHL by age 50, and the prevalence rises to over 80% by age 70 [4].

Two FDA-approved pharmacologic treatments exist for MPHL. Finasteride 1 mg daily (Propecia) inhibits 5-alpha reductase type II, reducing scalp DHT by approximately 60-70%. The key Phase III trial (N=1,553) showed finasteride produced a statistically significant increase in hair count versus placebo at 12 months (P<0.001), with 83% of men maintaining or improving hair at two years [5]. Minoxidil 5% topical solution or foam applied twice daily (once daily for the foam formulation) is the second FDA-approved option; its mechanism likely involves opening potassium channels in the follicle, extending the anagen phase and increasing follicular size.

Oral minoxidil at low doses (0.625-2.5 mg daily) is increasingly used off-label based on case series and a randomized trial (N=96) showing comparable efficacy to 5% topical minoxidil with better adherence [6]. A board-certified dermatologist at a major academic center noted in a 2022 commentary in the Journal of the American Academy of Dermatology: "Low-dose oral minoxidil represents a practical alternative for patients who find topical application cosmetically unacceptable." The same study reported a 9% rate of hypertrichosis at body sites other than the scalp, which is generally mild and reversible on discontinuation.

Dutasteride 0.5 mg daily inhibits both 5-alpha reductase type I and II, reducing DHT by roughly 90%. It is FDA-approved for benign prostatic hyperplasia and is used off-label for MPHL; a 2021 meta-analysis in the Journal of Dermatological Treatment found dutasteride produced greater hair count increases than finasteride at 24 weeks across four included trials [7].

Female Pattern Hair Loss: Recognition and Treatment Options

Female pattern hair loss (FPHL) presents as diffuse thinning over the crown and frontal scalp with preservation of the frontal hairline, classified by the Ludwig scale (I through III). About 40% of women show some degree of FPHL by age 70, and the condition can cause significant psychological distress [8]. Free androgen levels are elevated in only about 40% of women with FPHL, meaning many cases reflect follicular sensitivity rather than absolute androgen excess.

The only FDA-approved topical treatment for FPHL is minoxidil 2% solution applied twice daily or minoxidil 5% foam applied once daily. The 2023 American Academy of Dermatology (AAD) guidelines recommend minoxidil as first-line pharmacologic therapy [9]. Oral spironolactone 100-200 mg daily is widely used off-label for women with FPHL and elevated androgens; a randomized trial (N=80) published in the Journal of the American Academy of Dermatology (2015) showed 44% of women on spironolactone had improvement in hair density at 12 months versus 26% on placebo [10].

Women of childbearing age on spironolactone require reliable contraception because of teratogenic risk, specifically feminization of a male fetus. Finasteride is not FDA-approved for women and is contraindicated in pregnancy. Some postmenopausal women are treated with finasteride 1-2.5 mg daily off-label, though evidence remains thinner than for MPHL [11].

Platelet-rich plasma (PRP) injections, given in a series of three sessions four to six weeks apart, have shown statistically significant improvements in hair density in a meta-analysis of 11 randomized controlled trials (N=370) published in Aesthetic Surgery Journal (2019) [12]. PRP is not FDA-cleared as a drug for FPHL, but the procedure itself uses the patient's own blood components.

Telogen Effluvium: Temporary Shedding After a Systemic Trigger

Telogen effluvium (TE) is the second most common form of hair loss seen in clinical practice. A physiological or psychological stressor shifts a disproportionate number of hair follicles from the anagen phase into the telogen (resting) phase prematurely. Shedding begins 2-4 months after the triggering event, as telogen hairs are shed when new anagen growth pushes them out.

Common triggers include major surgery, childbirth, rapid weight loss (>1 kg/week sustained), severe infection (including COVID-19), thyroid dysfunction, iron deficiency (ferritin <30 ng/mL is associated with TE in multiple observational studies), and psychological stress [13]. A prospective study of 216 COVID-19 survivors found that 22% reported notable hair shedding at the 60-day post-discharge mark, consistent with acute TE following systemic illness [14].

The hair pull test is positive in active TE, yielding more than 6 telogen hairs (club roots visible under magnification) per 60-hair pull. Trichoscopy shows an increased proportion of yellow dots and a lack of miniaturization, distinguishing TE from androgenetic alopecia.

Treatment is primarily addressing the underlying cause. Correcting iron deficiency to a ferritin above 70 ng/mL is a common clinical target. Thyroid normalization with levothyroxine is appropriate when TSH is outside the reference range. Topical minoxidil 5% can shorten the recovery period by immediately recruiting telogen follicles back into anagen, though it does not address the root trigger. Most cases resolve within 6-12 months if the stressor is removed.

Chronic telogen effluvium (CTE) persists beyond 6 months and often lacks an identifiable trigger. It tends to cycle, with periods of intense shedding alternating with relative stability. CTE rarely progresses to permanent hair loss, and reassurance combined with nutritional optimization forms the backbone of management.

Alopecia Areata: Autoimmune Follicular Attack

Alopecia areata (AA) is an autoimmune condition in which T-cell-mediated inflammation targets the hair follicle bulb, causing focal, non-scarring hair loss. The lifetime risk is approximately 2%, making it one of the most common autoimmune disorders globally [15]. AA presents as round or oval patches of complete hair loss, most often on the scalp, though eyebrows, eyelashes, and body hair can be affected. Alopecia totalis (complete scalp loss) and alopecia universalis (total body hair loss) are severe spectrum variants.

The nail finding of geometric pitting (30 or more pits) is present in roughly 10-20% of AA patients and provides a useful clinical clue. Trichoscopy shows yellow dots, black dots, broken hairs, and exclamation mark hairs at the periphery of active patches.

For limited AA affecting <50% of scalp, intralesional corticosteroid injections (triamcinolone acetonide 5-10 mg/mL, injected every 4-6 weeks) are the standard of care and produce regrowth in 60-70% of patients with patchy disease [16]. Topical high-potency corticosteroids (clobetasol propionate 0.05%) are used for children or adults averse to injections, though response rates are lower.

The JAK inhibitor baricitinib (Olumiant) received FDA approval in June 2022 for severe AA (affecting 50% or more of scalp), the first-ever FDA-approved systemic treatment for the condition. The BRAVE-AA1 trial (N=654) showed that 38.8% of patients on baricitinib 4 mg reached a SALT (Severity of Alopecia Tool) score of 20 or less at week 36, versus 6.6% on placebo (P<0.001) [17]. Ritlecitinib (Litfulo), a JAK3/TEC inhibitor, received FDA approval in June 2023 for AA in patients age 12 and older; the ALLEGRO trial (N=718) showed 23% of patients on ritlecitinib 50 mg achieved a SALT score of 10 or less at week 24 versus 1.6% on placebo [18].

Treating Hirsutism: Anti-Androgens, Cosmetic Options, and Monitoring

First-line pharmacologic treatment for hirsutism is an oral contraceptive pill (OCP) containing a progestin with low androgenic activity, such as norgestimate, desogestrel, or drospirenone. OCPs suppress LH-driven ovarian androgen production and raise SHBG, reducing free testosterone. The Endocrine Society guidelines recommend OCPs as initial therapy for women not seeking fertility [1].

When OCP monotherapy is insufficient after six months, spironolactone 100-200 mg daily is added. Spironolactone blocks the androgen receptor and weakly inhibits 5-alpha reductase. A Cochrane systematic review (N=272, six RCTs) found spironolactone significantly reduced the mFG score compared to placebo (mean difference -7.2 points, 95% CI: -8.9 to -5.5) [19]. Patients must be monitored for hyperkalemia, especially if they have chronic kidney disease or are taking ACE inhibitors. Monthly potassium checks for the first three months are standard practice at most centers.

Eflornithine hydrochloride 13.9% cream (Vaniqa) is FDA-approved for reduction of unwanted facial hair in women. It inhibits ornithine decarboxylase in the hair follicle and slows hair growth without removing existing hair. The key trial (N=594) showed 32% of women had marked improvement at 24 weeks versus 8% on vehicle (P<0.001) [20]. It is used as an adjunct to laser hair removal, not a replacement.

Laser hair removal with Nd:YAG (1,064 nm) or alexandrite (755 nm) lasers is the most durable cosmetic option. Multiple sessions (typically 6-8, spaced 4-6 weeks apart) are needed because only follicles in the anagen phase respond. Darker skin types require longer-wavelength devices to avoid epidermal injury. Laser therapy does not address the hormonal root cause, so pharmacologic treatment should run concurrently.

Hair removal response to pharmacologic treatment should be assessed at 6-month intervals using the mFG score. Meaningful response is generally defined as a 3-point or greater reduction in mFG score. Testosterone levels are rechecked at three to six months to confirm biochemical response.

Nutritional and Lifestyle Factors Across All Hair Disorders

Nutritional deficiencies can worsen any hair disorder and are sometimes the primary driver of shedding. Iron deficiency is the most studied; a study published in the Journal of Korean Medical Science (N=210) found ferritin below 30 ng/mL in 59.8% of women with chronic TE but only 18.2% of controls (P<0.001) [13]. Zinc deficiency impairs DNA synthesis in rapidly proliferating follicle cells; serum zinc below 70 mcg/dL correlates with higher AA prevalence in one case-control study (N=200) [21].

Biotin deficiency is genuinely rare outside of hereditary biotinidase deficiency or prolonged raw egg white consumption, yet biotin supplementation is widely self-prescribed. The FDA issued a safety communication in 2019 warning that high-dose biotin (>30 mcg/day) interferes with thyroid and troponin immunoassays, producing falsely low or high results [22]. Clinicians should ask about biotin use before ordering these tests.

Protein intake below 0.8 g/kg/day is associated with TE in rapid weight-loss contexts. GLP-1 receptor agonist therapy (semaglutide, tirzepatide) produces rapid caloric restriction and weight loss that can trigger TE in a minority of patients; ensuring adequate protein (at least 1.2 g/kg ideal body weight/day) and monitoring ferritin levels every three months during active weight loss may reduce this risk.